REDUCE-IT
Abstract
The Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT) has established a new standard of care in addressing residual risk in patients with elevated triglycerides already treated with statins.1,2 The study found that icosapent ethyl, a highly purified ethyl ester of eicosapentaenoic acid (EPA), reduced the risk of major adverse cardiovascular events (MACE) by 25%. This included a statistically significant 20% reduction in death from cardiovascular causes, as well as statistically significant reductions in a variety of other prespecified endpoints, including a 31% reduction in myocardial infarction (MI), a 28% reduction in stroke, a 32% reduction in hospitalization for unstable angina, and a 35% reduction in urgent or emergent coronary revascularization. REDUCE-IT randomized 8179 patients with established atherosclerosis or diabetes mellitus plus at least one additional risk factor, who had fasting triglyceride levels of 1.52 to 5.63 mmol/L (135–499 mg/dL) while on statin therapy, to either icosapent ethyl or placebo. A high proportion (43%) of patients screened were randomized, suggesting good generalizability of the trial findings. The median follow-up was 4.9 years.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There is substantial residual risk in these patients that potentially could be addressed if they were identified and treated with icosapent ethyl.
“Thus, there is substantial residual risk in these patients that potentially could be addressed if they were identified and treated with icosapent ethyl.18”
From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [18]
Cited by
Sorted by citations
Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid
Mason, R. P., Libby, P., & Bhatt, D. L. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313286 · Cited by 407 · see citing works
Self-citationREDUCE-IT USA: Results From the 3146 Patients Randomized in the United States
Bhatt, D. L., Miller, M., Brinton, E. A., Jacobson, T. A., Steg, P. G., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044440 · Cited by 136 · see citing works
Self-citationMineral oil: safety and use as placebo in REDUCE-IT and other clinical studies
Olshansky, B., Chung, M. K., Budoff, M. J., Philip, S., Jiao, L., Doyle, Jr., Copland, C., Giaquinto, A., Juliano, R. A., & Bhatt, D. L. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa117 · Cited by 103 · see citing works
Self-citationGaba, P., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.035 · Cited by 61 · see citing works
Self-citationLakshmanan, S., Shekar, C., Kinninger, A., Dahal, S., Onuegbu, A., Cai, A. N., Hamal, S., Birudaraju, D., Roy, S. K., Nelson, J. R., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvz329 · Cited by 42 · see citing works
Self-citationCardiovascular risk reduction with icosapent ethyl
Patel, P. N., Patel, S. M., & Bhatt, D. L. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000678 · Cited by 33 · see citing works
Self-citationDagenais, G. R., Rydén, L., Leiter, L. A., Lakshmanan, M., Dyal, L., Probstfield, J. L., Atisso, C. M., Shaw, J. E., Conget, I., Cushman, W. C., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01179-1 · Cited by 35 · see citing works
- Authors
- Bhatt, D. L.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Bhatt, Deepak L
- ORCID
- Bhatt, Deepak L
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-04-14
- Volume
- 40
- Issue
- 15
- Pages
- 1174-1175
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2936852091
- Cited by
- 37
- References
- 0
- Citations by year
- 2025: 2 · 2023: 2 · 2022: 7 · 2021: 9 · 2020: 11 · 2019: 6
- FWCI
- 6.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- European Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- icosapent ethyl, eicosapentaenoic acid, residual cardiovascular risk, hypertriglyceridemia, statin-treated patients, major adverse cardiovascular events, myocardial infarction, stroke, unstable angina, coronary revascularization, omega-3 fatty acids, REDUCE-IT trial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
